{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:54:35Z","timestamp":1790704475013,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust -","doi-asserted-by":"crossref","award":["214321\/Z\/18\/Z Recipient Prof Graeme Meintjes"],"award-info":[{"award-number":["214321\/Z\/18\/Z Recipient Prof Graeme Meintjes"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV-associated tuberculosis (TB) contributes disproportionately to global tuberculosis mortality. Patients hospitalised at the time of the diagnosis of HIV-associated disseminated TB are typically severely ill and have a high mortality risk despite initiation of tuberculosis treatment. The objective of the study is to assess the safety and efficacy of both intensified TB treatment (high dose rifampicin plus levofloxacin) and immunomodulation with corticosteroids as interventions to reduce early mortality in hospitalised patients with HIV-associated disseminated TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a phase III randomised controlled superiority trial, evaluating two interventions in a 2 \u00d7 2 factorial design: (1) high dose rifampicin (35 mg\/kg\/day) plus levofloxacin added to standard TB treatment for the first 14 days versus standard tuberculosis treatment and (2) adjunctive corticosteroids (prednisone 1.5 mg\/kg\/day) versus identical placebo for the first 14 days of TB treatment. The study population is HIV-positive patients diagnosed with disseminated TB (defined as being positive by at least one of the following assays: urine Alere LAM, urine Xpert MTB\/RIF Ultra or blood Xpert MTB\/RIF Ultra) during a hospital admission. The primary endpoint is all-cause mortality at 12 weeks comparing, first, patients receiving intensified TB treatment to standard of care and, second, patients receiving corticosteroids to those receiving placebo. Analysis of the primary endpoint will be by intention to treat. Secondary endpoints include all-cause mortality at 2 and 24 weeks. Safety and tolerability endpoints include hepatoxicity evaluations and corticosteroid-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Disseminated TB is characterised by a high mycobacterial load and patients are often critically ill at presentation, with features of sepsis, which carries a high mortality risk. Interventions that reduce this high mycobacterial load or modulate associated immune activation could potentially reduce mortality. If found to be safe and effective, the interventions being evaluated in this trial could be easily implemented in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT04951986. Registered on 7 July 2021<\/jats:p>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04951986\">https:\/\/clinicaltrials.gov\/study\/NCT04951986<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-024-08119-4","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T07:01:46Z","timestamp":1715151706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4024-0626","authenticated-orcid":false,"given":"Phiona E.","family":"Namale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Boloko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate A.","family":"Haigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortuna","family":"Bagula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Maseko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Sossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lee-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoliswa","family":"Msomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayanda Trevor","family":"Mnguni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Crede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Naude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakeena","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakoob","family":"Vallie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Shiraz","family":"Moosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Bandeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel","family":"Hoosain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazlee","family":"Samodien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Centner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentzel","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freedom","family":"Gumedze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arifa","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denzil","family":"Schietekat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryony","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Oliphant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siphokazi","family":"Hlungulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy","family":"Apolisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Toleni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimkhitha","family":"Asare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mkanyiseli Kenneth","family":"Mpalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Boshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Prinsloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Lakay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abulele","family":"Bekiswa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"issue":"1","key":"8119_CR1","doi-asserted-by":"publisher","first-page":"20714","DOI":"10.7448\/IAS.19.1.20714","volume":"19","author":"N Ford","year":"2016","unstructured":"Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.","journal-title":"J Int AIDS Soc."},{"issue":"7","key":"8119_CR2","doi-asserted-by":"publisher","first-page":"e0132394","DOI":"10.1371\/journal.pone.0132394","volume":"10","author":"JJR Bigna","year":"2015","unstructured":"Bigna JJR, Noubiap JJN, Agbor AA, Plottel CS, Billong SC, Ayong APR, Koulla-Shiro S. Early mortality during initial treatment of tuberculosis in patients co-infected with HIV at the Yaound\u00e9 Central Hospital, Cameroon: an 8-year retrospective cohort study (2006-2013). PLoS One. 2015;10(7):e0132394.","journal-title":"PLoS One."},{"issue":"4","key":"8119_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/QAI.0000000000000763","volume":"70","author":"S Subbarao","year":"2015","unstructured":"Subbarao S, Wilkinson KA, Van Halsema CL, Rao SS, Boyles T, Utay NS, et al. Raised venous lactate and markers of intestinal translocation are associated with mortality among in-patients with HIV-associated TB in rural South Africa. J Acquir Immune Defic Syndr. 2015;70(4):406.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"7","key":"8119_CR4","doi-asserted-by":"publisher","first-page":"e1002840","DOI":"10.1371\/journal.pmed.1002840","volume":"16","author":"C Schutz","year":"2019","unstructured":"Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, et al. Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. PLoS Med. 2019;16(7):e1002840.","journal-title":"PLoS Med."},{"issue":"4","key":"8119_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/QAI.0b013e3181eb611a","volume":"55","author":"R Kyeyune","year":"2010","unstructured":"Kyeyune R, den Boon S, Cattamanchi A, Davis JL, Worodria W, Yoo SD, Huang L. Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr. 2010;55(4):446.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"8119_CR6","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/cid\/ciz1133","volume":"71","author":"A Gupta-Wright","year":"2020","unstructured":"Gupta-Wright A, Fielding K, Wilson D, van Oosterhout JJ, Grint D, Mwandumba HC, et al. Tuberculosis in hospitalized patients with human immunodeficiency virus: clinical characteristics, mortality, and implications from the rapid urine-based screening for tuberculosis to reduce AIDS related mortality in hospitalized patients in Africa. Clin Infect Dis. 2020;71(10):2618\u201326.","journal-title":"Clin Infect Dis."},{"issue":"15","key":"8119_CR7","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1097\/QAD.0000000000000802","volume":"29","author":"RK Gupta","year":"2015","unstructured":"Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987\u20132002.","journal-title":"AIDS."},{"issue":"7","key":"8119_CR8","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2666-5247(22)00062-3","volume":"3","author":"L Boloko","year":"2022","unstructured":"Boloko L, Schutz C, Sibiya N, Balfour A, Ward A, Shey M, et al. Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study. Lancet Microbe. 2022;3(7):e521-ee32.","journal-title":"Lancet Microbe."},{"key":"8119_CR9","doi-asserted-by":"publisher","first-page":"103949","DOI":"10.1016\/j.ebiom.2022.103949","volume":"78","author":"DA Barr","year":"2022","unstructured":"Barr DA, Schutz C, Balfour A, Shey M, Kamariza M, Bertozzi CR, et al. Serial measurement of M. tuberculosis in blood from critically-ill patients with HIV-associated tuberculosis. EBioMedicine. 2022;78:103949.","journal-title":"EBioMedicine."},{"issue":"8","key":"8119_CR10","doi-asserted-by":"publisher","first-page":"e70305","DOI":"10.1371\/journal.pone.0070305","volume":"8","author":"ST Jacob","year":"2013","unstructured":"Jacob ST, Pavlinac PB, Nakiyingi L, Banura P, Baeten JM, Morgan K, et al. Mycobacterium tuberculosis bacteremia in a cohort of HIV-infected patients hospitalized with severe sepsis in Uganda\u2013high frequency, low clinical sand derivation of a clinical prediction score. PloS One. 2013;8(8):e70305.","journal-title":"PloS One."},{"issue":"13","key":"8119_CR11","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.2017.10913","volume":"318","author":"B Andrews","year":"2017","unstructured":"Andrews B, Semler MW, Muchemwa L, Kelly P, Lakhi S, Heimburger DC, et al. Effect of an early resuscitation protocol on in-hospital mortality among adults with sepsis and hypotension: a randomized clinical trial. Jama. 2017;318(13):1233\u201340.","journal-title":"Jama."},{"issue":"2","key":"8119_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","volume":"3","author":"G Acocella","year":"1978","unstructured":"Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978;3(2):108\u201327.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"8119_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","volume":"17","author":"MJ Boeree","year":"2017","unstructured":"Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39\u201349.","journal-title":"Lancet Infect Dis."},{"issue":"12","key":"8119_CR14","doi-asserted-by":"publisher","first-page":"e01014","DOI":"10.1128\/AAC.01014-18","volume":"62","author":"S Dian","year":"2018","unstructured":"Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, et al. Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis. Antimicrob Agents Chemother. 2018;62(12):e01014\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"8119_CR15","doi-asserted-by":"crossref","unstructured":"Te Brake LH, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PP, et al. Increased bactericidal activity but dose-limiting intolerability at 50 mg\u00b7 kg\u2212 1 rifampicin. Eur Respir J. 2021;58(1).","DOI":"10.1183\/13993003.00955-2020"},{"issue":"4","key":"8119_CR16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/cpt.778","volume":"103","author":"RJ Svensson","year":"2018","unstructured":"Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH. A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses. Clin Pharmacol Ther. 2018;103(4):674\u201383.","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"8119_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/AAC.01830-15","volume":"60","author":"MT Chirehwa","year":"2016","unstructured":"Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H, Denti P. Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction. Antimicrob Agents Chemother. 2016;60(1):487\u201394.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"8119_CR18","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","volume":"47","author":"R Jayaram","year":"2003","unstructured":"Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118\u201324.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"8119_CR19","first-page":"352","volume":"131","author":"M Tsukamura","year":"1985","unstructured":"Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis. 1985;131(3):352\u20136.","journal-title":"Am Rev Respir Dis."},{"issue":"6","key":"8119_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1128\/AAC.39.6.1341","volume":"39","author":"B Ji","year":"1995","unstructured":"Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995;39(6):1341\u20134.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"8119_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/jac\/26.2.227","volume":"26","author":"WW Yew","year":"1990","unstructured":"Yew WW, Kwan SY-L, Ma WK, Khin MA, Chan PY. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother. 1990;26(2):227\u201336.","journal-title":"J Antimicrob Chemother."},{"issue":"3","key":"8119_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/jac\/34.3.343","volume":"34","author":"W Yew","year":"1994","unstructured":"Yew W, Piddock L, Li M, Lyon D, Chan C, Cheng A. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother. 1994;34(3):343\u201351.","journal-title":"J Antimicrob Chemother."},{"issue":"11","key":"8119_CR23","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1164\/rccm.200305-682OC","volume":"168","author":"RD Gosling","year":"2003","unstructured":"Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003;168(11):1342\u20135.","journal-title":"Am J Respir Crit Care Med."},{"issue":"17","key":"8119_CR24","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","volume":"371","author":"CS Merle","year":"2014","unstructured":"Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588\u201398.","journal-title":"N Engl J Med."},{"issue":"17","key":"8119_CR25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577\u201387.","journal-title":"N Engl J Med."},{"issue":"17","key":"8119_CR26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","volume":"371","author":"A Jindani","year":"2014","unstructured":"Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599\u2013608.","journal-title":"N Engl J Med."},{"issue":"6","key":"8119_CR27","doi-asserted-by":"publisher","first-page":"832","DOI":"10.5588\/ijtld.15.0577","volume":"20","author":"A Jindani","year":"2016","unstructured":"Jindani A, Borgulya G, de Patino IW, Gonzales T, de Fernandes RA, Shrestha B, et al. A randomised phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. Int J Tuberc Lung Dis. 2016;20(6):832\u20138.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"3","key":"8119_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/jac\/44.3.393","volume":"44","author":"S Gillespie","year":"1999","unstructured":"Gillespie S, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother. 1999;44(3):393\u20135.","journal-title":"J Antimicrob Chemother."},{"issue":"10","key":"8119_CR29","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1093\/jac\/dkr281","volume":"66","author":"R Cremades","year":"2011","unstructured":"Cremades R, Rodr\u00edguez JC, Garc\u00eda-Pach\u00f3n E, Galiana A, Ruiz-Garc\u00eda M, L\u00f3pez P, Royo G. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother. 2011;66(10):2281\u20133.","journal-title":"J Antimicrob Chemother."},{"issue":"18","key":"8119_CR30","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, Phillips PP, Bryant K, Dooley KE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705\u201318.","journal-title":"N Engl J Med."},{"issue":"8","key":"8119_CR31","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1086\/521894","volume":"45","author":"H Nijland","year":"2007","unstructured":"Nijland H, Ruslami R, Suroto AJ, Burger D, Alisjahbana B, Van Crevel R, Aarnoutse RJ. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45(8):1001\u20137.","journal-title":"Clin Infect Dis."},{"issue":"5","key":"8119_CR32","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jac\/dkx004","volume":"72","author":"A Naidoo","year":"2017","unstructured":"Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, et al. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. J Antimicrob Chemother. 2017;72(5):1441\u20139.","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"8119_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/0091270004264643","volume":"44","author":"GJ Noel","year":"2004","unstructured":"Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol. 2004;44(5):464\u201373.","journal-title":"J Clin Pharmacol."},{"key":"8119_CR34","first-page":"2020","volume-title":"FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients","author":"FDA U","year":"2018","unstructured":"FDA U. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. FDA Drug Safety Communication; 2018. p. 2020."},{"issue":"15","key":"8119_CR35","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","volume":"85","author":"R Sutter","year":"2015","unstructured":"Sutter R, R\u00fcegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology. 2015;85(15):1332\u201341.","journal-title":"Neurology."},{"issue":"12","key":"8119_CR36","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMoa1407380","volume":"371","author":"BM Mayosi","year":"2014","unstructured":"Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121\u201330.","journal-title":"N Engl J Med."},{"issue":"15","key":"8119_CR37","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","volume":"24","author":"G Meintjes","year":"2010","unstructured":"Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, et al. Randomized placebo-controlled trial of prednisone for paradoxical TB-associated immune reconstitution inflammatory syndrome. AIDS (London, England). 2010;24(15):2381.","journal-title":"AIDS (London, England)."},{"key":"8119_CR38","doi-asserted-by":"crossref","unstructured":"Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4.","DOI":"10.1002\/14651858.CD002244.pub4"},{"key":"8119_CR39","doi-asserted-by":"crossref","unstructured":"Wiysonge CS, Ntsekhe M, Thabane L, Volmink J, Majombozi D, Gumedze F, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017;9.","DOI":"10.1002\/14651858.CD000526.pub2"},{"issue":"20","key":"8119_CR40","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa1800762","volume":"379","author":"G Meintjes","year":"2018","unstructured":"Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):1915\u201325.","journal-title":"N Engl J Med."},{"key":"8119_CR41","volume-title":"Cochrane Database of Systematic Reviews","author":"A Stern","year":"2017","unstructured":"Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. In: Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2017."},{"key":"8119_CR42","doi-asserted-by":"crossref","unstructured":"Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. 2015;12.","DOI":"10.1002\/14651858.CD002243.pub3"},{"issue":"21","key":"8119_CR43","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"P-F Dequin","year":"2023","unstructured":"Dequin P-F, Meziani F, Quenot J-P, Kamel T, Ricard J-D, Badie J, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931\u201341.","journal-title":"N Engl J Med."},{"issue":"4","key":"8119_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","volume":"33","author":"AL Buchman","year":"2001","unstructured":"Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289\u201394.","journal-title":"J Clin Gastroenterol."},{"issue":"6","key":"8119_CR45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/WCO.0b013e32833e5a5d","volume":"23","author":"P Roth","year":"2010","unstructured":"Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010;23(6):597\u2013602.","journal-title":"Curr Opin Neurol."},{"key":"8119_CR46","doi-asserted-by":"crossref","unstructured":"Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;4.","DOI":"10.1002\/14651858.CD006150.pub2"},{"issue":"21","key":"8119_CR47","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJM199011223232104","volume":"323","author":"SA Bozzette","year":"1990","unstructured":"Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323(21):1451\u20137.","journal-title":"N Engl J Med."},{"issue":"12","key":"8119_CR48","doi-asserted-by":"publisher","first-page":"e28570","DOI":"10.1371\/journal.pone.0028570","volume":"6","author":"CT Costiniuk","year":"2011","unstructured":"Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count< 200 cells\/\u03bcL and virologic suppression: a systematic review. PloS one. 2011;6(12):e28570.","journal-title":"PloS one."},{"issue":"10","key":"8119_CR49","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/17476348.2018.1515628","volume":"12","author":"C Schutz","year":"2018","unstructured":"Schutz C, Davis AG, Sossen B, Lai RP, Ntsekhe M, Harley YX, Wilkinson RJ. Corticosteroids as an adjunct to tuberculosis therapy. Expert Rev Respir Med. 2018;12(10):881\u201391.","journal-title":"Expert Rev Respir Med."},{"issue":"4","key":"8119_CR50","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1086\/515543","volume":"25","author":"DP Dooley","year":"1997","unstructured":"Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis. 1997;25(4):872\u201387.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"8119_CR51","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1128\/AAC.48.3.780-782.2004","volume":"48","author":"MW Pletz","year":"2004","unstructured":"Pletz MW, De Roux A, Roth A, Neumann K-H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother. 2004;48(3):780\u20132.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"8119_CR52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2020.09.016","volume":"183","author":"CR Consiglio","year":"2020","unstructured":"Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183(4):968\u201381 e7.","journal-title":"Cell."},{"issue":"23","key":"8119_CR53","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255\u201373.","journal-title":"N Engl J Med."},{"issue":"8","key":"8119_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"Group RC","year":"2021","unstructured":"Group RC. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med."},{"key":"8119_CR55","unstructured":"Western Cape Government, Provincial TB dashboard. Number of tuberculosis (TB) cases in the Western Cape 2023 [cited 2023 05\/07\/2023]. Available from: https:\/\/www.westerncape.gov.za\/site-page\/provincial-tb-dashboard."},{"key":"8119_CR56","doi-asserted-by":"crossref","unstructured":"Mnguni AT, Schietekat D, Ebrahim N, Sonday N, Boliter N, Schrueder N, Gabriels S, Sigwadhi LN, Zemlin AE, Chapanduka ZC, Ngah V. The clinical and epidemiological characteristics of a series of patients living with HIV admitted for COVID-19 in a district hospital. BMC Infect Dis. 2023;23(1):123.","DOI":"10.1186\/s12879-023-08004-6"},{"key":"8119_CR57","volume-title":"Treatment of tuberculosis: guidelines","author":"Organization WH","year":"2010","unstructured":"Organization WH, Initiative ST. Treatment of tuberculosis: guidelines. World Health Organization; 2010."},{"key":"8119_CR58","unstructured":"Africa DoHS. National Tuberculosis Management Guidelines: National Department of Health; 2013 [Guideline]. [cited\u00a0 2023 1\/10\/2023]. Available from: https:\/\/knowledgehub.health.gov.za\/system\/files\/elibdownloads\/2023-04\/National%252520TB%252520management%252520guidelines%2525202014.pdf."},{"issue":"8","key":"8119_CR59","doi-asserted-by":"publisher","first-page":"e00140","DOI":"10.1128\/AAC.00140-21","volume":"65","author":"S Wasserman","year":"2021","unstructured":"Wasserman S, Davis A, Stek C, Chirehwa M, Botha S, Daroowala R, et al. Plasma pharmacokinetics of high-dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial. Antimicrob Agents Chemother. 2021;65(8):e00140\u2013e00121.","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"8119_CR60","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1128\/AAC.01833-10","volume":"55","author":"E Chigutsa","year":"2011","unstructured":"Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother. 2011;55(9):4122\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"8119_CR61","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.200709-1311PP","volume":"177","author":"SD Lawn","year":"2008","unstructured":"Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and \u201cunmasking\u201d of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med. 2008;177(7):680\u20135.","journal-title":"Am J Respir Crit Care Med."},{"issue":"8","key":"8119_CR62","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1128\/AAC.01474-06","volume":"51","author":"A Diacon","year":"2007","unstructured":"Diacon A, Patientia R, Venter A, Van Helden P, Smith P, McIlleron H, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007;51(8):2994\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"8119_CR63","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1128\/AAC.05526-11","volume":"56","author":"H McIlleron","year":"2012","unstructured":"McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012;56(6):3232\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"8119_CR64","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5588\/ijtld.17.0697","volume":"22","author":"R Court","year":"2018","unstructured":"Court R, Chirehwa MT, Wiesner L, Wright B, Smythe W, Kramer N, McIlleron H. Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. Int J Tuberc Lung Dis. 2018;22(5):537\u201343.","journal-title":"Int J Tuberc Lung Dis."},{"key":"8119_CR65","unstructured":"Health NDo. 2023 ART Clinical Guidelines for the Management of HIV in Adults, Pregnancy, Breastfeeding, Adolescents, Children, Infants and Neonates. 2023. [cited 2023 1\/10\/2023]. Available from: https:\/\/knowledgehub.health.gov.za\/system\/files\/elibdownloads\/2023-07\/National%20ART%20Clinical%20Guideline%20AR%204.5%2020230713%20Version%204%20WEB.pdf."},{"issue":"1","key":"8119_CR66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/01.qai.0000230521.86964.86","volume":"43","author":"W Manosuthi","year":"2006","unstructured":"Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV\/tuberculosis-coinfected patients with and without antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2006;43(1):42\u20136.","journal-title":"JAIDS J Acquir Immune Defic Syndr."},{"issue":"8","key":"8119_CR67","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","volume":"8","author":"G Meintjes","year":"2008","unstructured":"Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516\u201323.","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"8119_CR68","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935\u201352.","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"8119_CR69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jinf.2018.06.009","volume":"77","author":"I Rizvi","year":"2018","unstructured":"Rizvi I, Malhotra HS, Garg RK, Kumar N, Uniyal R, Pandey S. Fluoroquinolones in the management of tuberculous meningitis: systematic review and meta-analysis. J Infect. 2018;77(4):261\u201375.","journal-title":"J Infect."},{"key":"8119_CR70","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivist\u00f6 KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819\u201350.","journal-title":"Clin Pharmacokinet."},{"issue":"7","key":"8119_CR71","doi-asserted-by":"publisher","first-page":"871","DOI":"10.5588\/ijtld.10.0352","volume":"15","author":"C Waitt","year":"2011","unstructured":"Waitt C, Squire S. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 2011;15(7):871\u201385.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"12","key":"8119_CR72","doi-asserted-by":"publisher","first-page":"e15241","DOI":"10.1371\/journal.pone.0015241","volume":"5","author":"M Straetemans","year":"2010","unstructured":"Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One. 2010;5(12):e15241.","journal-title":"PLoS One."},{"key":"8119_CR73","volume-title":"Open forum infectious diseases","author":"FV Cresswell","year":"2020","unstructured":"Cresswell FV, Ellis J, Kagimu E, Bangdiwala AS, Okirwoth M, Mugumya G, et al. Standardized urine-based tuberculosis (TB) screening with TB-lipoarabinomannan and Xpert MTB\/RIF Ultra in Ugandan adults with advanced human immunodeficiency virus disease and suspected meningitis. In: Open forum infectious diseases. Oxford University Press US; 2020."},{"key":"8119_CR74","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijid.2018.07.007","volume":"75","author":"RR Atherton","year":"2018","unstructured":"Atherton RR, Cresswell FV, Ellis J, Skipper C, Tadeo KK, Mugumya G, et al. Detection of Mycobacterium tuberculosis in urine by Xpert MTB\/RIF Ultra: a useful adjunctive diagnostic tool in HIV-associated tuberculosis. Int J Infect Dis. 2018;75:92\u20134.","journal-title":"Int J Infect Dis."},{"key":"8119_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijid.2018.08.005","volume":"75","author":"TH Boyles","year":"2018","unstructured":"Boyles TH, Griesel R, Stewart A, Mendelson M, Maartens G. Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV. Int J Infect Dis. 2018;75:67\u201373.","journal-title":"Int J Infect Dis."},{"key":"8119_CR76","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s10461-020-03101-y","volume":"25","author":"M Fiorentino","year":"2021","unstructured":"Fiorentino M, Nishimwe M, Protopopescu C, Iwuji C, Okesola N, Spire B, et al. Early ART initiation improves HIV status disclosure and social support in people living with HIV, linked to care within a universal test and treat program in rural South Africa (ANRS 12249 TasP Trial). AIDS Behavior. 2021;25:1306\u201322.","journal-title":"AIDS Behavior."},{"issue":"1","key":"8119_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-020-00274-3","volume":"17","author":"T Girum","year":"2020","unstructured":"Girum T, Yasin F, Wasie A, Shumbej T, Bekele F, Zeleke B. The effect of \u201cuniversal test and treat\u201d program on HIV treatment outcomes and patient survival among a cohort of adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South Ethiopia. AIDS Res Ther. 2020;17(1):1\u20139.","journal-title":"AIDS Res Ther."},{"issue":"4","key":"8119_CR78","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/cid\/civ911","volume":"62","author":"J-P Lanoix","year":"2016","unstructured":"Lanoix J-P, Chaisson RE, Nuermberger EL. Shortening tuberculosis treatment with fluoroquinolones: lost in translation? Clin Infect Dis. 2016;62(4):484\u201390.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"8119_CR79","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2174\/156652407780598575","volume":"7","author":"KJ Williams","year":"2007","unstructured":"Williams KJ, Duncan K. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr Mol Med. 2007;7(3):297\u2013307.","journal-title":"Curr Mol Med."},{"issue":"6","key":"8119_CR80","first-page":"605","volume":"10","author":"J Johnson","year":"2006","unstructured":"Johnson J, Hadad D, Boom W, Daley C, Peloquin C, Eisenach K, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006;10(6):605\u201312.","journal-title":"Int J Tuberc Lung Dis."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08119-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08119-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08119-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T03:19:53Z","timestamp":1731899993000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08119-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8119"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08119-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3869003\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the trial was obtained from the University of Cape Town Faculty of Health Sciences Human Research Ethical Committee, before the trial was initiated (Ref: 001\/2021). The trial adheres to ICH Good Clinical Practice guidelines, South African GCP guidelines of 2019 and the Declaration of Helsinki of hs018. Regulatory approval for the trial was obtained from the South African Health Products Authority (Tracking number: 20210328).This trial is registered with Clinical Trials.gov NCT04951986 and the South African National Clinical Trials Register (SANCTR) DOH-27072021-4806.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable\u2014no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"There are no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"311"}}